Fighting Cancer with Nanomedicine

Nanotechnology-based therapeutics will revolutionize cancer treatment.

By | April 1, 2014


Short drug circulation times and difficulty localizing therapy to tumor sites are but two of the challenges associated with existing cancer treatments. More troubling are the issues of drug toxicity and tumor resistance. Toxicity can cause major complications, such as low white-blood-cell counts or heart fail­ure, that necessitate cessation of treatment. The tissue damage inflicted by some therapies can even be fatal. And evolution of drug resistance by tumors accounts for the vast majority of cases in which treatment fails. Given these and other issues associated with treatment safety and efficacy, scientists are applying tremendous effort toward the utilization of nanomedicine in the fight against cancer.

Nanotechnology-based therapeutics have exhibited clear benefits when compared with unmodified drugs, including improved half-lives, retention, and targeting efficiency, and fewer patient side effects. Researchers have already made progress with chemotherapeutic nanomedicines in the clinic. Several compounds that are in various stages of trials or already approved by the U.S. Food and Drug Administration (FDA). For example, Calando Pharmaceuticals has demonstrated the first evidence of nanoparticle-delivered clinical RNA interference (RNAi) (Nature, 464:1067-70, 2010). BIND Biosciences has shown that nanoparticles combining a chemotherapeutic drug with prostate-specific membrane antigen (PSMA) can reduce lung and tonsillar lesions with greater efficacy compared with the drug alone, and at substantially lower doses (Sci Transl Med, doi:10.1126/scitranslmed.3003651, 2012). Furthermore, Celgene’s Abraxane, an albumin-functionalized paclitaxel formulation, was initially approved by the FDA for sale as a breast cancer therapy, but also recently received approval for the treatment of lung and pancreatic cancers.

Cancer nanomedicine possesses the versatility required to uniquely overcome some of the most challenging impediments to treatment success.

On the preclinical front, several nanomaterial formulations have shown promise. Single-agent nanoparticle delivery, both actively and passively targeted, has been demonstrated with a host of platforms using silica, polymer, metal, and carbon-based materials.

Delivering a double whammy

Researchers recently reported multidrug delivery using nanoparticles to mediate resistance in relapsing cancers and to improve triple-negative breast cancer treatment efficacy. Other recent approaches have included layer-by-layer siRNA and doxorubicin delivery for breast cancer therapy, simultaneous loading of small interfering RNA (siRNA) and tumor-penetrating peptides against ovarian cancer, as well as sequential administration of multiple types of nanoparticles for pancreatic cancer treatment (Adv Funct Mater, doi:10.1002/adfm.201303222, 2014). These exciting approaches have served as a foundation for the next phase of cancer nanomedicine in the clinic—the rational design of nanomaterial-drug combinations.

Until more nanoparticles are validated in the clinic, however, the impact that nanomedicine may have on cancer treatment has yet to be fully realized. In order for chemotherapies modified using nanotechnology to profoundly change hematological and oncological practice, the application of engineered nanomedicines must be paired with emerging strategies to rationally design nanotherapeutic combinations. This is critical because combinatorial therapy is an efficient way to simultaneously address the barriers to treatment success, and it is widely used in treating cancer and infectious diseases.

Current clinical methodologies for combinatorial drug design include additive treatments that combine two or more drugs at their highest tolerable but still efficacious dose, although the synergistic effects among drugs cannot be taken into account using this additive approach. As the field gradually embraces the use of nanoparticles to deliver multiple compounds with different targets, a move away from additive dosing is necessary. This raises several important questions. For example, silencing genes to combat resistance, mediating apoptosis, and allowing vascular access are each pathways worth targeting, but what if multiple pathways are targeted at the same time to comprehensively attack the tumor? How will dosing be determined? How will the dosages of each drug be adjusted if efficacy is improved but toxicity is worsened? More importantly, how will “optimization” be defined, especially if the desired outcome is to simultaneously stop tumor growth, eliminate resistance, maintain white blood cell counts, and achieve a host of other objectives?

The next phase of cancer nanomedicine in the clinic is the rational design of nanomaterial-drug combinations.

An attempt to optimize any one of these conditions will inevitably affect the others. Furthermore, these conditions vary from patient to patient, so phenotypic personalized medicine will be required. In addition, these issues create a parameter space that is too large to be individually tested and can result in an arbitrary dosing scenario. For example, a combination of six candidate therapeutics with 10 possible concentrations represents a minimum of 1 million possible combinations. Identifying a solution that rapidly converges on a defined set of phenotypic outcomes is a challenge that faces both unmodified drug administration and drug delivery by nanoparticles.

To move beyond short-term cancer management—or single outcomes, like delaying tumor growth using a nanoparticle drug formulation—and to enable long-term or potentially permanent disease management, the field of nanomedicine will inevitably need to be paired with advanced strategies to rapidly determine dosing conditions that can simultaneously optimize for efficacy and safety. One promising route is the field of feedback system control (FSC), which relies on phenotypic responses instead of trying to interrogate cellular pathways, their individual protein components, or a spectrum of genotypic responses. One example is the use of a search algorithm in a feedback loop that can guide the formulation of rational drug combinations, both unmodified and nanotherapeutic. (See PNAS, 105:5105-10, 2008; BMC Systems Biology, 5:88, 2011.) Remarkably, this approach can be used for in vitro studies with cell lines and primary cells, and for preclinical and even clinical validation. And because FSC utilizes outcomes to iteratively suggest new possible combinations before rapid convergence—in tens of trials versus a million or more—toward an optimal combinatorial dose, pharmacokinetics and pharmacodynamics are inherently accounted for with this approach. Furthermore, because combinations will vary from patient to patient, FSC will help personalized nanomedicine dosing on a case-by-case basis.

In sum, cancer nanomedicine possesses the versatility required to uniquely overcome some of the most challenging impediments to treatment success. Rationally designing nanotherapeutic combinations using rapid convergence solutions such as FSC represents a promising pathway from cancer management towards cancer elimination.

Dean Ho is a professor of oral biology and medicine at the University of California, Los Angeles (UCLA) School of Dentistry, where he codirects the Weintraub Center for Reconstructive Biotechnology. He is also a UCLA professor of bioengineering and a member of the Jonsson Comprehensive Cancer Center and California NanoSystems Institute. In December 2013, Ho coauthored a review of the translation of cancer nanomedicine to the clinic (E.K. Chow, D. Ho, Sci Transl Med, doi:10.1126/scitranslmed.3005872, 2013).

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


Avatar of: DR.R.A.RAO


Posts: 1

September 19, 2014

very informative and interesting.

Avatar of: Ferromagnetism


Posts: 4

December 29, 2015

Nanotechnology-based therapeutics will revolutionize cancer treatment? See: Cancer Drug Resistance and Iron-Deficiency Treatments. There is no single treatment for cancer, and patients often receive a combination of therapies. The National Cancer Institute (NCI) is the nation's leader in cancer research. According to the NCI, resistant cancer (refractory cancer) is cancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment. Despite all that is known about the different ways cancer genes work, many cancers cannot be linked to a specific gene. Cancer loves iron, the Father of Oncology explains. At the cellular level, cancer occurs when cellular iron overload chaotically affects cellular molecules and organelles (DNA, chromosomes, mitochondria, etc). Researchers and scientists describe chaos in DNA and chromosomes as the emergence of new mutations. Chaos is a state of extreme confusion. Confusion can increase slowly over time (benign tumor cells). Cancer is a disease of iron-overloaded cells. Primary tumors always develop at body sites of excessive iron deposits; such deposits can be inherited or acquired. Of course, cancer may be resistant at the beginning of inadequate treatment, or it may become resistant during inadequate treatment (chemotherapy, radiotherapy, targeted therapy). Surgery is the oldest type of cancer therapy and remains an effective treatment for many types of cancer today. Cancer may be successfully treated with surgery (ceramic blades) and direct intratumoral injections of iron-deficiency substances (ceramic needles). Personalized clinical iron-deficiency methods (special diets, blood donations) can successfully neutralize micro-metastases. Iron-deficiency methods can neutralize HIV and ALS (Amyotrophic Lateral Sclerosis). Viruses and bacteria need iron for survival, growth and multiplication. Iron overload increases post-transplant infection risk. Iron deficiency is the enemy of HIV and antibiotic resistant bacteria (bacteria that are not controlled or killed by antibiotics). There is no cure or effective treatment for ALS, experts say. ALS is a progressive neurodegenerative disease that affects iron-overloaded nerve cells in the brain and the spinal cord, the Father of Oncology explains. ALS is a form of cancer. ALS-related iron overload can be inherited or acquired, but familial and sporadic forms of ALS are clinically and pathologically similar  

Popular Now

  1. Antarctica Is Turning Green
  2. How to Tell a Person’s “Brain Age”
  3. Male Fish Borrows Egg to Clone Itself
  4. Life Science Funding Cuts Leaked
    The Nutshell Life Science Funding Cuts Leaked

    According to a document posted online less than a day before the release of the official 2018 budget proposal, the National Institutes of Health could face even deeper cuts than previously suggested by the Trump administration.